Table 1 Baseline characteristics in patients with thyroidectomy history according to secondary cancer in Korean national cohort after matching.
Second primary cancer | P-value | ||
|---|---|---|---|
Absence (n = 47,160) | Presence (n = 11,790) | ||
Age at surgery, mean ± SD | 53.1 ± 11.4 | 53.1 ± 11.5 | |
≤ 40 | 5800 (12.30) | 1450 (12.30) | |
40 < and ≤ 60 | 27,228 (57.74) | 6807 (57.74) | |
60 < | 14,132 (29.97) | 3533 (29.97) | |
Sex, n (%) | |||
Men | 9212 (19.53) | 2303 (19.53) | |
Women | 37,948 (80.47) | 9487 (80.47) | |
Hospital scalea at surgery, n (%) | < 0.001 | ||
Tertiary | 30,461 (64.59) | 7261 (61.59) | |
General | 14,209 (30.13) | 3886 (32.96) | |
Community | 1617 (3.43) | 452 (3.83) | |
Clinics | 873 (1.85) | 191 (1.62) | |
Obesity, n (%) | 84 (0.18) | 21 (0.18) | 1.000 |
Hypertension, n (%) | 16,484 (34.95) | 4450 (37.74) | < 0.001 |
Diabetes mellitus, n (%) | 8671 (18.39) | 2370 (20.10) | < 0.001 |
Dyslipidemia, n (%) | 18,203 (38.60) | 4675 (39.65) | 0.037 |
Infectionsb, n (%) | 2058 (4.36) | 728 (6.17) | < 0.001 |
Duration of levothyroxine, n (%) | |||
Mean ± SD (days) | 1187.0 ± 916.8 | 1203.0 ± 926.6 | 0.091 |
No | 2674 (5.67) | 580 (4.92) | 0.009 |
≤ 1 year | 7357 (15.60) | 1877 (15.92) | |
1 < and ≤ 5 years | 26,049 (55.24) | 6493 (55.07) | |
5 years < | 11,080 (23.49) | 2840 (24.09) | |
Daily average dose of levothyroxine, n (%) | |||
Mean ± SD | 125.8 ± 56.5 | 129.9 ± 55.9 | < 0.001 |
No | 2674 (5.67) | 580 (4.92) | < 0.001 |
≤ 50 μg | 1626 (3.45) | 450 (3.82) | |
50 μg < and ≤ 100 μg | 8489 (18.00) | 1898 (16.10) | |
100 μg < | 34,371 (72.88) | 8862 (75.17) | |
RAI cumulative dose, n (%) | < 0.001 | ||
≤ 30 mCi | 35,610 (75.51) | 8560 (72.60) | |
30 mCi < and ≤ 100 mCi | 5717 (12.12) | 1425 (12.09) | |
100 mCi < and ≤ 150 mCi | 4261 (9.04) | 1176 (9.97) | |
150 mCi < | 1572 (3.33) | 629 (5.34) | |
